The Biopharma Gap Eastern India Hasn't Noticed
India has world-class pharmaceutical clusters in Hyderabad, Pune, and Ahmedabad. Eastern India has none. That gap is also an opening, and Odisha is positioned to claim it.
Founder, Majhi Group & Majhi OS
Draw a line east of Hyderabad and look for a dedicated pharmaceutical or biotechnology manufacturing cluster. You will not find one. Not in West Bengal. Not in Jharkhand. Not in Chhattisgarh. Not in Odisha.
Eastern India, home to several hundred million people, with significant mineral and agricultural resources, and a coastline that connects to Southeast Asia, has no serious biopharma cluster. The entire eastern region is a gap in India's pharmaceutical industrial map.
That gap is also the opening.
Where India's pharma strength lives
India is the world's third-largest pharmaceutical producer by volume and among the largest exporters of generic medicines globally. The industry is genuinely world-class. But it is geographically concentrated in ways that are rarely examined.
Hyderabad's Genome Valley and the surrounding pharmaceutical industrial estate have made the city the dominant hub, hosting the bulk of India's vaccine manufacturing capacity and a significant share of its biotech research. Pune has a substantial cluster, with strong connections to the chemicals industry in western Maharashtra. Ahmedabad and the broader Gujarat corridor handle a large share of API (active pharmaceutical ingredient) manufacturing. Bengaluru has built research capability.
The pattern is clear: pharma clusters in western and southern India, research in the south, almost nothing in the east.
This is partly historical. Hyderabad's cluster began with deliberate state investment in the 1990s. Gujarat's chemical industry had infrastructure that made the transition to pharma manufacturing natural. Bengaluru's technology ecosystem extended into biotech. Eastern India lacked the equivalent catalysts.
But the conditions that produced those catalysts elsewhere are now available in Odisha in ways they were not two decades ago.
Why Odisha fits
First-mover arguments require more than an empty map. They require actual conditions that make the claimed position viable.
Odisha has a genuine case.
Port infrastructure is the starting point. Paradip is among the largest ports in India and handles significant industrial cargo. For a capital-intensive industry like biopharma, which depends on imports of raw material and intermediates and needs to export finished product, proximity to port infrastructure is a meaningful cost advantage. Hyderabad's pharmaceutical clusters are landlocked. Odisha's industrial zones can be port-adjacent.
The state has industrial land at scale. Odisha has been developing large-format industrial corridors along the coast, Dhamra, Gopalpur, Paradip, that have the land, power, and basic infrastructure that pharmaceutical manufacturing requires. The land acquisition challenges that hobble industrial development elsewhere in India are less acute here.
Water and power, both critical inputs for biotech manufacturing, are available. Odisha has historically had power surplus. The water-rich river systems of the state are an asset that pharma manufacturing consumes heavily.
The talent argument is the weakest part of the case, but it is not absent. Odisha produces significant numbers of science graduates, from KIIT, SOA, Utkal, Sambalpur, who currently migrate to work in pharma clusters elsewhere. A cluster in Odisha would not need to create the talent pool from scratch; it would need to retain what the state already produces.
What the moment is
India's Union Budget has in recent years signaled serious intent on building pharmaceutical and vaccine manufacturing capacity, specifically for export, and specifically to reduce dependence on Chinese API imports. That policy direction reduces investment risk for a new cluster. It means central government support for infrastructure, for PLI (production-linked incentive) schemes, for the regulatory environment that makes the investment viable.
The window created by that policy intent is not permanent. The states that move first to position themselves as the implementation sites for this ambition will capture the cluster formation. States that wait will find that the geography has been claimed.
The history of how industrial clusters form is consistent on this point: they form once, in a specific place, for path-dependent reasons, and they are extremely difficult to dislodge once formed. Hyderabad's pharma cluster exists because of decisions made in the 1990s. No one is rebuilding it in a different city.
Eastern India has a one-time opening to claim this. The biological reason it has not been claimed yet, no existing cluster to build around, is also the reason the claim is available.
The question of initiative
Industrial clusters do not form purely from geographic logic. They form because someone, a state government, a set of anchor investors, a combination of both, makes a deliberate choice to create the conditions and then does the work of attracting the first major investments that make the rest follow.
Odisha has done this before in steel, in aluminum, in power generation. The model is understood. The difference with biopharma is that the window is earlier and the first-mover advantage is larger, because the eastern India gap means there is genuinely no incumbent to compete against.
The case for Odisha as the biopharma capital of eastern India is not aspirational in the way that development targets sometimes are. It is geographically grounded, industrially coherent, and politically timely.
The question is not whether the opportunity exists. The question is whether it gets claimed before the moment passes.
That is a choice, not a forecast.
Industrial clusters form once, in a specific place, for path-dependent reasons - and they are nearly impossible to dislodge once formed. Eastern India has a one-time opening. The question is whether it gets claimed before the moment passes.
See also: Beyond GDP: What a Developed Odisha Must Be Answerable For, Odisha Manufacturing: The Industrial Engine of Eastern India, Odisha's Untapped Potential
Sources
India Brand Equity Foundation: Pharmaceuticals Industry in India
Pharmexcil (Pharmaceuticals Export Promotion Council of India): Annual Report
Government of India: Production Linked Incentive (PLI) Scheme for Pharmaceuticals
Frequently Asked Questions
Why is there no pharmaceutical or biotech manufacturing cluster in eastern India despite the region's size?
It is partly historical and partly momentum-dependent. Hyderabad's cluster began with deliberate state investment in the 1990s; Gujarat's chemical industry had pre-existing infrastructure that made pharma manufacturing a natural extension; Bengaluru's tech ecosystem extended into biotech. Eastern India lacked equivalent catalysts at the time when cluster formation happened. Industrial clusters form once, in a specific place, for path-dependent reasons, and are extremely difficult to dislodge once formed. The eastern India gap persists because the window to form the first cluster passed without the necessary combination of investment, policy, and infrastructure being in place simultaneously.
What makes Odisha specifically positioned for a biopharma cluster in eastern India?
Four concrete advantages. Port infrastructure: Paradip is among India's largest ports and handles significant industrial cargo; for a capital-intensive industry that depends on raw material imports and product exports, port-adjacent industrial zones are a meaningful cost advantage over landlocked clusters like Hyderabad. Industrial land: Odisha has large-format industrial corridors (Dhamra, Gopalpur, Paradip) with the land, power, and basic infrastructure pharmaceutical manufacturing requires, without the land acquisition challenges that hobble industrial development elsewhere. Water and power: both critical for biotech manufacturing, available at scale. And a talent pool: Odisha science graduates currently migrate to pharma clusters elsewhere; a cluster here retains what the state already produces rather than creating talent from scratch.
Why does the timing window matter and what closes it?
India's Union Budget has signaled serious intent on building pharmaceutical and vaccine manufacturing capacity for export and to reduce dependence on Chinese API imports. That policy direction, including PLI schemes and central government infrastructure support, reduces investment risk for a new cluster and creates a window. But the states that move first to position themselves as implementation sites for this ambition will capture the cluster formation. Once a cluster forms in any eastern Indian state, or once the window of PLI incentives closes, the path-dependent dynamics that make industrial clusters so durable will have set. Eastern India has a one-time opening precisely because no existing cluster has been established. The question is not whether the opportunity exists. The question is whether it gets claimed before the moment passes.
Did this land? Push back? Add something I missed?
Reply to Manas →Continue Reading
Related writing
OdishaParadip: The Port Odisha Has Not Captured
Paradip Port is India's largest port by cargo volume, handling over 150 million metric tonnes annually. It sits on Odisha's coastline, routing the state's mineral wealth to the world. And yet Odisha remains one of India's least economically developed states. That gap between what Paradip handles and what Odisha captures is the central strategic question of Odisha's economic future.
OdishaWhy Is Odisha Underrated?
Odisha is systematically underestimated, not because it lacks substance, but because it lacks the visibility infrastructure that translates substance into perception. The gap between what the state is and what most people believe about it is large and narrowing.
OdishaBeyond GDP: What a Developed Odisha Must Be Answerable For
Economic growth is necessary for development. But it is not a definition of it. Odisha has been growing. The harder question is what that growth has actually built.